Andrew Baum

Novartis Profit Rises 7% on Lack of Generic Diovan

Novartis AG’s first-quarter profit rose 7 percent as a generic challenger to the company’s second- best-selling medicine failed to enter the market.

Glaxo Rises After Lung Drug Gets FDA Panel Backing: London Mover

GlaxoSmithKline Plc rose to the highest price in 11 years after advisers to the U.S. Food and Drug Administration recommended that experimental treatment Breo Ellipta be approved to treat a lung disorder.

Pfizer Experimental Drug Slows Late-Stage Breast Cancer

Pfizer Inc.’s experimental breast cancer drug stopped progression of an incurable form of the disease for more than two years in a study, a dramatic delay for those with the second-deadliest cancer in women.

Merck KGaA Woos Investors Irked by `Bunker' Culture, Dearth of New Drugs

Merck KGaA Chief Financial Officer- designate Matthias Zachert may make his first task repairing the German company’s relationship with investors and analysts as he seeks to revive one of Europe’s worst-performing drug stocks.

Novartis Smoker’s Cough Treatment Beats Glaxo’s Advair in Trial

Patients taking Novartis AG’s experimental once-daily treatment for smoker’s cough showed a significant improvement in lung function over those on an existing medicine marketed by GlaxoSmithKline Plc, which is also developing a successor drug.

Roche Embraces Genentech Innovation to Keep Cancer Drug Pipeline Flowing

When Roche Holding AG executives held an investor-day briefing in New York in March, Morgan Stanley analyst Andrew Baum had a question that had nothing to do with new drugs, licensing deals or health-care legislation.

Pfizer May Push $5 Billion Breast Cancer Hope for Ruling

Pfizer Inc., the world’s largest drugmaker, is weighing whether to ask U.S. regulators to expedite their review of a potential $5 billion-a-year treatment to slow a type of incurable breast cancer.

Cancer Tools Help Roche Push Ahead With Alzheimer’s Drug

Roche Holding AG is focusing part of its pipeline on the riskiest area of drug development: the human brain.

Glaxo Melanoma Drugs Beat Standard Chemotherapy in Study

Two experimental GlaxoSmithKline Plc drugs that block genes tied to lethal skin cancer worked better than chemotherapy in studies that tested them individually, paving the way for final-phase trials on their use together.

AstraZeneca's Brennan Poaches Pfizer to Renew Failing Research

David Brennan couldn’t sit still. During a meal of beef and potatoes at AstraZeneca Plc’s drug research center near Stockholm in October, Brennan, the company’s chief executive officer, grilled six drug-development managers over a concern raised by a laboratory scientist.

"All divisions were strong with the exception of Alcon, which was hampered by sluggish revenues in the surgical business."

- Andrew Baum on Apr 24, 2013

London

New Jersey

Boston

California

Singapore Police Accessed Todd’s Hard Drive, FBI Says

U.S. Stocks Drop as Reports Show Manufacturing Contracts

Squeezed Tesla Bears Buying $276 Million Hand Musk 146% Gain

Google Said to Plan Debuting Music Service Rivaling Spotify

WTI Crude Near Two-Week Low; Europe Probes Oil Pricing